Keir M E, Butte M J, Freeman G J, et al. PD-1 and Its Ligands in Tolerance and Immunity[J]. Annual review of immunology, 2008,26(1):677-704.
Steidl C, Shah S P, Woolcock B W, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers[J]. Nature, 2011,471(7338):377-381.
Wu Y, Chen W, Xu Z P, et al. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition[J]. Frontiers in immunology, 2019,10:2022.
Nowicki T S, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade[J]. Cancer J, 2018,24(1):47-53.
Guzik K, Tomala M, Muszak D, et al. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles[J]. Molecules, 2019,24(11).
Tan P S, Aguiar P J, Haaland B, et al. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants[J]. Lung Cancer, 2018,115:84-88.
Jiang T, Jia Q, Fang W, et al. Pan-cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment[J]. Clin Transl Med, 2020.
Yarchoan M, Hopkins A, Jaffee E M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition[J]. N Engl J Med, 2017,377(25):2500-2501.
Derosa L, Hellmann M D, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J]. Ann Oncol, 2018,29(6):1437-1444.
Verheijden R J, May A M, Blank C U, et al. Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry[J]. Clin Cancer Res, 2020,26(9):2268-2274.
Chalabi M, Cardona A, Nagarkar D R, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials[J]. Ann Oncol, 2020,31(4):525-531.
Patel S P, Othus M, Chae Y K, et al. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors[J]. Clin Cancer Res, 2020,26(10):2290-2296.
Kelly C M, Antonescu C R, Bowler T, et al. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial[J]. JAMA oncology, 2020,6(3):402-408.
Xu G, Feng D, Yao Y, et al. Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization[J]. Oncogene, 2020,39(7):1429-1444.